AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling

April 7, 2025 8:18 am Published by

Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. 2025. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000.

Categorised in:

This post was written by Heike Ufheil